Biogen Idec (BIIB) was downgraded by Piper Jaffray (PJC) to neutral from overweight, as the share price has been approacing the previously set $168 price target. Shares are lower by about 1.3 percent.
Biogen Idec (BIIB) was downgraded by Piper Jaffray (PJC) to neutral from overweight, as the share price has been approacing the previously set $168 price target. Shares are lower by about 1.3 percent.
